102 related articles for article (PubMed ID: 10516682)
1. Accurate quantitation of residual tumor burden at bone marrow harvest predicts timing of subsequent relapse in patients with common ALL treated by autologous bone marrow transplantation. Nagoya BMT Group.
Mizuta S; Ito Y; Kohno A; Kiyoi H; Miyamura K; Tanimoto M; Takamatsu J; Naoe T; Morishima Y; Ueda R; Saito H
Bone Marrow Transplant; 1999 Oct; 24(7):777-84. PubMed ID: 10516682
[TBL] [Abstract][Full Text] [Related]
2. Detection of minimal residual disease in patients with childhood common acute lymphoblastic leukemia after autologous bone marrow transplantation with ex vivo purging and systemic IL-2 infusion: unsuccessful prediction of subsequent relapse.
Kiyoi H; Kojima S; Kato K; Matsuyama T; Kodera Y; Ohno R; Naoe T
Bone Marrow Transplant; 1995 Sep; 16(3):437-42. PubMed ID: 8535317
[TBL] [Abstract][Full Text] [Related]
3. Pretransplantation burden of leukemic progenitor cells as a predictor of relapse after bone marrow transplantation for acute lymphoblastic leukemia.
Uckun FM; Kersey JH; Haake R; Weisdorf D; Nesbit ME; Ramsay NK
N Engl J Med; 1993 Oct; 329(18):1296-301. PubMed ID: 8413410
[TBL] [Abstract][Full Text] [Related]
4. Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse.
Miglino M; Berisso G; Grasso R; Canepa L; Clavio M; Pierri I; Pietrasanta D; Gatto S; Varaldo R; Ballerini F; Verdiani S; Casarino L; DeStefano F; Sessarego M; Dominietto A; Raiola AM; Bregante S; di Grazia C; Gobbi M; Bacigalupo A
Bone Marrow Transplant; 2002 Nov; 30(9):579-85. PubMed ID: 12407432
[TBL] [Abstract][Full Text] [Related]
5. Purging in BCR-ABL-positive acute lymphoblastic leukemia using immunomagnetic beads: comparison of residual leukemia and purging efficiency in bone marrow vs peripheral blood stem cells by semiquantitative polymerase chain reaction.
Atta J; Fauth F; Keyser M; Petershofen E; Weber C; Lippok G; Hoelzer D; Martin H
Bone Marrow Transplant; 2000 Jan; 25(1):97-104. PubMed ID: 10654022
[TBL] [Abstract][Full Text] [Related]
6. Treatment of childhood acute lymphoblastic leukemia after the first relapse: curative strategies.
Uderzo C; Dini G; Locatelli F; Miniero R; Tamaro P
Haematologica; 2000 Nov; 85(11 Suppl):47-53. PubMed ID: 11268324
[TBL] [Abstract][Full Text] [Related]
7. The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.
Lee S; Kim YJ; Chung NG; Lim J; Lee DG; Kim HJ; Min CK; Lee JW; Min WS; Kim CC
Cancer; 2009 Feb; 115(3):561-70. PubMed ID: 19117346
[TBL] [Abstract][Full Text] [Related]
8. Disappearance of minimal residual lymphoblastic leukemia cells 6 months after allogeneic bone marrow transplantation without GVHD.
Kiyoi H; Naoe T; Kitamura K; Yamauchi T; Ichihashi T; Ohno R
Bone Marrow Transplant; 1991 Jul; 8(1):59-62. PubMed ID: 1912956
[TBL] [Abstract][Full Text] [Related]
9. Mixed chimerism in the B cell lineage is a rapid and sensitive indicator of minimal residual disease in bone marrow transplant recipients with pre-B cell acute lymphoblastic leukemia.
Zetterquist H; Mattsson J; Uzunel M; Näsman-Björk I; Svenberg P; Tammik L; Bayat G; Winiarski J; Ringdén O
Bone Marrow Transplant; 2000 Apr; 25(8):843-51. PubMed ID: 10808205
[TBL] [Abstract][Full Text] [Related]
10. Role of autologous bone marrow transplantation as consolidation therapy in acute promyelocytic leukemia patients in complete remission.
Ottaviani E; Martinelli G; Testoni N; Visani G; Tani M; Tura S
Haematologica; 1998 Nov; 83(11):1051-5. PubMed ID: 9864933
[TBL] [Abstract][Full Text] [Related]
11. Autologous bone marrow transplantation for high risk acute lymphoblastic leukemia: clinical relevance of ex vivo bone marrow purging with monoclonal antibodies and complement.
Grañena A; Castellsagué X; Badell I; Ferra C; Ortega J; Brunet S; Puntí C; Sureda A; Picón M; Valls A; Rutllant M; García J
Bone Marrow Transplant; 1999 Sep; 24(6):621-7. PubMed ID: 10490727
[TBL] [Abstract][Full Text] [Related]
12. Allogeneic and autologous bone marrow transplantation after consolidation therapy in high-risk acute myeloid leukemia in children. Towards a risk-oriented therapy.
Ortega JJ; Díaz de Heredia C; Olivé T; Bastida P; Llort A; Armadans L; Torrabadella M; Massuet L
Haematologica; 2003 Mar; 88(3):290-9. PubMed ID: 12651268
[TBL] [Abstract][Full Text] [Related]
13. Value of autologous stem cell transplantation with purged bone marrow as first-line therapy for follicular lymphoma with high tumor burden: a GOELAMS phase II study.
Colombat P; Cornillet P; Deconinck E; Tourani JM; Gardembas M; Delain M; Abgrall JF; Kootz C; Milpied N
Bone Marrow Transplant; 2000 Nov; 26(9):971-7. PubMed ID: 11100276
[TBL] [Abstract][Full Text] [Related]
14. Autologous bone marrow transplantation in ALL: relapse linked to infusion of tumor cells with the back-up marrow.
Grande M; Barbu V; Van den Akker J; Laporte JP; Douay L; Lopez M; Lesage S; Isnard F; Stachowiak J; Lemoine F
Bone Marrow Transplant; 1994 Sep; 14(3):477-80. PubMed ID: 7994277
[TBL] [Abstract][Full Text] [Related]
15. Randomized study of recombinant interleukin-2 after autologous bone marrow transplantation for acute leukemia in first complete remission.
Blaise D; Attal M; Reiffers J; Michallet M; Bellanger C; Pico JL; Stoppa AM; Payen C; Marit G; Bouabdallah R; Sotto JJ; Rossi JF; Brandely M; Hercend T; Maraninchi D
Eur Cytokine Netw; 2000 Mar; 11(1):91-8. PubMed ID: 10705305
[TBL] [Abstract][Full Text] [Related]
16. A comparison of chimerism and minimal residual disease between four different allogeneic transplantation methods in patients with chronic myelogenous leukemia in first chronic phase.
Elmaagacli AH; Runkel K; Steckel N; Opalka B; Trenschel R; Seeber S; Schaefer UW; Beelen DW
Bone Marrow Transplant; 2001 Apr; 27(8):809-15. PubMed ID: 11477437
[TBL] [Abstract][Full Text] [Related]
17. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Ringdén O; Labopin M; Gorin NC; Le Blanc K; Rocha V; Gluckman E; Reiffers J; Arcese W; Vossen JM; Jouet JP; Cordonnier C; Frassoni F
J Clin Oncol; 2004 Feb; 22(3):416-23. PubMed ID: 14691124
[TBL] [Abstract][Full Text] [Related]
18. Autologous bone marrow transplantation for childhood acute lymphoblastic leukemia: a novel combined approach consisting of ex vivo marrow purging, modulation of multi-drug resistance, induction of autograft vs leukemia effect, and post-transplant immuno- and chemotherapy (PTIC).
Houtenbos I; Bracho F; Davenport V; Slack R; van de Ven C; Suen Y; Killen R; Shen V; Cairo MS
Bone Marrow Transplant; 2001 Jan; 27(2):145-53. PubMed ID: 11281383
[TBL] [Abstract][Full Text] [Related]
19. Rituximab can be useful as treatment for minimal residual disease in bcr-abl-positive acute lymphoblastic leukemia.
Jándula BM; Nomdedeu J; Marín P; Vivancos P
Bone Marrow Transplant; 2001 Jan; 27(2):225-7. PubMed ID: 11281397
[TBL] [Abstract][Full Text] [Related]
20. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
